摘要
生物制剂是一种选择性针对参与免疫反应或炎症过程的分子或以受体为靶目标的单克隆抗体或天然抑制分子的重组产物。生物制剂种类繁多,主要针对细胞因子,B细胞和共刺激信号分子,包括:肿瘤坏死因子抑制剂、抗白细胞介素6(IL-6)受体单克隆抗体和抗CD20单克隆抗体利妥昔单抗等多种药物,主要用于治疗强直性脊柱炎、类风湿关节炎和系统性红斑狼疮等自身免疫性疾病。生物制剂的使用应关注其安全性,用药前进行结核筛查,除外活动性感染和肿瘤。生物制剂的减停药问题有待探讨。
Biological agent is a recombinant product that is selectively targeted to the immune response or to the inflammatory process,or to the target of a monoclonal antibody or a natural inhibitor of the target.The biologic drugs have wide variety,the major targets of most biologic therapies are cytokines,B cells and co-stimulation molecules,including tumor necrosis factor（TNF）inhibitors,anti-interleukin-6 receptor monoclonal antibody,anti-CD20 antibodies rutximab and other drugs.They are prescribed for the treatment of rheumatoid arthritis,ankylosing spondylitis,systemic lupus erythematosus and other autoimmune disease.The use of biological agents should pay attention to safety.It is necessary to screen tuberculosis and exclude active infections and cancer before the use of biologic agents.Reduction dose or stopping biological drug need to be discussed.
出处
《临床荟萃》
CAS
2016年第5期490-495,共6页
Clinical Focus
关键词
生物制品
肿瘤坏死因子类
关节炎
类风湿
脊柱炎
biological products
tumor necrosis factors
arthritis
rheumatoid
spondylitis
作者简介
通信作者：靳洪涛，Email：15803210963@163．com
